CN113166151B - 经取代的黄嘌呤衍生物 - Google Patents

经取代的黄嘌呤衍生物 Download PDF

Info

Publication number
CN113166151B
CN113166151B CN201980081737.1A CN201980081737A CN113166151B CN 113166151 B CN113166151 B CN 113166151B CN 201980081737 A CN201980081737 A CN 201980081737A CN 113166151 B CN113166151 B CN 113166151B
Authority
CN
China
Prior art keywords
mmol
mixture
esi
hplc
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980081737.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166151A (zh
Inventor
K·格拉赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Original Assignee
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyderabad Bioscience Co ltd, Boehringer Ingelheim International GmbH filed Critical Hyderabad Bioscience Co ltd
Publication of CN113166151A publication Critical patent/CN113166151A/zh
Application granted granted Critical
Publication of CN113166151B publication Critical patent/CN113166151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980081737.1A 2018-12-12 2019-12-10 经取代的黄嘌呤衍生物 Active CN113166151B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212060.0 2018-12-12
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (2)

Publication Number Publication Date
CN113166151A CN113166151A (zh) 2021-07-23
CN113166151B true CN113166151B (zh) 2023-12-01

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081737.1A Active CN113166151B (zh) 2018-12-12 2019-12-10 经取代的黄嘌呤衍生物

Country Status (18)

Country Link
US (2) US11198696B2 (https=)
EP (1) EP3894410B1 (https=)
JP (1) JP7502299B2 (https=)
KR (1) KR102877857B1 (https=)
CN (1) CN113166151B (https=)
AU (1) AU2019396499B2 (https=)
BR (1) BR112021008316A2 (https=)
CL (1) CL2021001509A1 (https=)
DK (1) DK3894410T3 (https=)
EA (1) EA202191588A1 (https=)
ES (1) ES2964630T3 (https=)
HU (1) HUE064908T2 (https=)
IL (1) IL283768B2 (https=)
MX (1) MX2021007019A (https=)
PH (1) PH12021551345A1 (https=)
PL (1) PL3894410T3 (https=)
TW (1) TWI825243B (https=)
WO (1) WO2020120450A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
WO2019011802A1 (en) * 2017-07-11 2019-01-17 Boehringer Ingelheim International Gmbh NEW SUBSTITUTED XANTHINE DERIVATIVES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023830A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
WO2019011802A1 (en) * 2017-07-11 2019-01-17 Boehringer Ingelheim International Gmbh NEW SUBSTITUTED XANTHINE DERIVATIVES

Also Published As

Publication number Publication date
IL283768A (en) 2021-07-29
IL283768B2 (en) 2024-05-01
HUE064908T2 (hu) 2024-04-28
US11198696B2 (en) 2021-12-14
DK3894410T3 (da) 2023-11-27
TWI825243B (zh) 2023-12-11
AU2019396499B2 (en) 2024-10-10
WO2020120450A1 (en) 2020-06-18
KR102877857B1 (ko) 2025-10-29
CA3119229A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
KR20210102955A (ko) 2021-08-20
BR112021008316A2 (pt) 2021-08-03
EP3894410A1 (en) 2021-10-20
PH12021551345A1 (en) 2022-05-11
JP2022512373A (ja) 2022-02-03
CN113166151A (zh) 2021-07-23
US20200190093A1 (en) 2020-06-18
MX2021007019A (es) 2021-09-10
ES2964630T3 (es) 2024-04-08
EA202191588A1 (ru) 2021-10-18
PL3894410T3 (pl) 2024-03-18
US20220177479A1 (en) 2022-06-09
JP7502299B2 (ja) 2024-06-18
EP3894410B1 (en) 2023-10-11
IL283768B1 (en) 2024-01-01
AU2019396499A1 (en) 2021-05-27
TW202039495A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
JP7114702B2 (ja) 新規置換キサンチン誘導体
CN113166151B (zh) 经取代的黄嘌呤衍生物
CA3145868A1 (en) N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxi n (atx) modulators for the treatment of inflammatory airway or fibrotic diseases
CA3146439A1 (en) 1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway diseases
EP3894409B1 (en) Substituted xanthine derivatives
CA3071074A1 (en) New propanamine derivatives for treating pain and pain related conditions
TW201504227A (zh) 環狀胺基甲基嘧啶衍生物
EP3700890B1 (en) Alcoxyamino derivatives for treating pain and pain related conditions
CA3119229C (en) Substituted xanthine derivatives
EA043969B1 (ru) Замещенные ксантиновые производные
JP2022509014A (ja) 疼痛及び疼痛に関連する状態を処置するための新規なアルコキシアミノピリジン誘導体
HK40025200A (en) Substituted xanthine derivatives
HK40025200B (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant